MA-CARE-ACCESS
18.3.2024 08:06:32 CET | Business Wire | Press release
Care Access, a global clinical research site company helping to accelerate the future of medicine, has opened its newest research site in Warsaw, Poland. The company’s expansion in Poland reinforces its commitment to improving access to clinical research globally through its innovative model of bringing clinical trials wherever they are needed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240318427054/en/
The Care Access - Warsaw research site is now open. (Photo: Business Wire)
In recent years, Care Access has been active in clinical research across Europe, and now, by establishing a new facility in Warsaw, Care Access is further expanding its European services aimed to implement its industry-leading research capabilities, such as its Community Screening Program, Sites On Demand, and Mobile Research Site Infrastructure. These capabilities have shown to accelerate research study enrollment by adapting to the unique makeup of each community and providing more convenient ways to participate in clinical trials.
“Poland plays an important role in bringing the future of medicine to reality,” said Rupi Bancil, Senior Vice President of Global Study Operations & Expansion for Care Access. “The Warsaw site will improve access to advanced health screenings and research opportunities to communities throughout Poland.”
Collaboration with local physicians is a key approach to how Care Access improves access to clinical research in more communities. With a centralized staff of research professionals and state-of-the-art equipment, infrastructure, and processes, Care Access takes on a great deal of the administrative and logistical burden so partnering physicians can spend more time focusing on their patients.
Care Access has previously expanded its global network of research sites through the acquisition of IBPClin in Brazil in 2022 and the establishment of its first Canadian research site in Cape Breton in 2023. The addition of the Warsaw location strengthens Care Access' global research site network, enabling the company to conduct trials across multiple therapeutic areas and respond to emerging global health needs.
About Care Access
Care Access is a global clinical research site company helping to accelerate the future of medicine. With a global network of over 200 research sites, Care Access supports research studies conducted by hundreds of top biopharmaceutical companies. In addition to its proven track record of globally top-enrolling sites, Care Access partners with new-to-research communities and establishes high-quality research site infrastructure locally to expand access to clinical trials and increase representation.
For research sponsors, Care Access offers three core services: (1) global network of research sites, (2) community screenings to expand a study’s reach, and (3) on-demand staffing, space expansion, and training services to support all research sites on a study.
To learn more about active studies at Care Access, or how Care Access helps sponsors achieve enrollment and representation goals, visit www.careaccess.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240318427054/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HyperLight Demonstrates Low-Power 1.6T-DR8 TFLN-based Reference Transceiver Assembled by TFC16.3.2026 13:03:00 CET | Press release
HyperLight Corporation (“HyperLight”) today announced a major milestone in low-power optical networking with the demonstration of a 1.6T-DR8 optical transceiver leveraging HyperLight’s TFLN Chiplet™ Platform. The reference module was demonstrated with engineering and manufacturing support from Suzhou TFC Optical Communication Co., Ltd. (SZSE: 300394, or "TFC"). The reference design achieves 20W power consumption in a fully retimed 1.6T-DR8 module, representing approximately 20% lower module-level power compared to alternative technologies. The reduction is achieved through a simple drop-in transmitter implementation based on a single thin-film lithium niobate photonic integrated circuit (TFLN PIC). The TFLN transmitter enables the module to operate using a single continuous-wave (CW) laser, compared to the two to four lasers typically required in conventional implementations. Additional energy savings are achieved through the ability to operate directly from the native low-swing electr
GCE® Launches Gascontrol.com Website Showcasing Its Complete Gas Control Portfolio for Speciality, Medical, and Industrial Applications16.3.2026 13:00:00 CET | Press release
GCE®, a global market leader for gas control equipment, has launched gascontrol.com, a new website designed to better serve customers across its GCE Specialty, GCE Medical, and GCE Industrial product portfolios. The new site provides a streamlined, market-focused experience that makes it easier for users to explore GCE’s gas control solutions and identify the right products. A new Documentation Search Tool assists customers in easily finding documents such as instructions for use (IFUs), appendices, and certifications through an intuitive search interface. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316410525/en/ GCE’s new website, gascontrol.com, provides a streamlined, market-focused experience across the GCE Specialty, GCE Medical, and GCE Industrial product portfolios. “The redesigned website reflects GCE’s role as a comprehensive, trusted supplier of gas control technologies that elevate industries and improve liv
SBC Medical Announces Opening of Brand Flagship "NEO Skin Clinic Ginza."16.3.2026 13:00:00 CET | Press release
Accelerating multi-branding strategy in aesthetic healthcare with global presence in Tokyo’s premier district SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, today announced that its specialized aesthetic brand, “NEO Skin Clinic,” will open its flagship location in Tokyo’s Ginza district, a globally recognized medical tourism hub and highly competitive district, on Saturday, March 28, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312457783/en/ SBC Medical Announces Opening of Brand Flagship "NEO Skin Clinic Ginza." The Ginza flagship, located in a prime area near GINZA SIX, will feature dedicated VIP rooms for executive clientele and the growing number of international patients, strengthening the brand’s global presence. Leveraging its robust network of 283 affilia
Lebrikizumab Delivered Significant Skin Clearance and Improved Disease Severity in Children With Moderate-to-severe Atopic Dermatitis16.3.2026 11:53:00 CET | Press release
Almirall announces positive, top-line results from Phase 3 ADorable-1 trialADorable-1 met co-primary efficacy endpoints, with 63% of paediatric patients achieving meaningful skin improvement (EASI-75) and 44% reaching clear or almost clear skin (IGA 0,1) at week 16.Key secondary endpoints showed significant itch relief (Pruritus NRS ≥4 point improvement), reduced overall disease severity (EASI-90) and improved quality of life (CDLQI ≥6-Point Improvement) in children and adolescents with moderate-to-severe atopic dermatitis treated with lebrikizumab.Skin conditions can have a profound physical and emotional impact on people’s lives1, and Atopic Dermatitis (AD) peaks in childhood – with around 60% of cases appearing within the first year of life2. Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today announced positive, top-line results from the pivotal Phase 3 ADorable-1 trial evaluating efficacy and safety of lebrikizumab for children and adoles
Experian Marks a Breakthrough in Consumer AI with the Next Evolution of Its Virtual Assistant16.3.2026 11:00:00 CET | Press release
Smarter, more adaptive assistant advances personalized, conversational financial guidance powered by trusted data Experian today unveiled the next evolution of the Experian Virtual Assistant, EVA™, a significant advancement in its Consumer First AI strategy that expands personalized, conversational financial guidance to millions of consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316538160/en/ Experian today unveiled the next evolution of the Experian Virtual Assistant, EVA™. “This next generation of EVA reflects the direction of our consumer AI strategy,” said Debbie Hsu, Executive Vice President of Product, Experian Consumer Services. “We are bringing together conversational AI, personalization, and our trusted data foundation to deliver guidance that is intuitive, relevant, and actionable. Our focus is on helping consumers make smarter financial decisions in ways that feel simple and empowering.” Built to scal
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
